

InnoCan Pharma

16:21 20 Aug 2020

Innocan Pharma strikes deal to distribute its SHIR line of CBD beauty products in Italy and Switzerland

Innocan Pharma Corporation (CSE:INNO) said Thursday that it inked a deal to distribute its CBD line of beauty and pharmaceutical products in Italy and Switzerland.

The distribution agreement with Cloud 9 Switzerland LLC will see it sell Innocan's SHIR Beauty and Relief & Go lines in the two countries, according to a release.

Iris Bincovich, Innocan's CEO, expressed the company's excitement to see its products distributed in Italy and Switzerland.

READ: Innocan Pharma subsidiary inks manufacturing and distribution deal with Calgary cannabis producer Endless Sky

"This is the second distribution agreement we have signed in Europe," Bincovich said in a statement. "I believe Cloud 9 will provide professional distribution of our SHIR and Relief & Go product lines."

Cloud 9 and its subsidiaries are active in the health and wellness sectors by developing, producing and commercialising hemp- and cannabis-based pharmaceuticals and nutraceuticals.

"In these extraordinary times, cannabis-based pharma and cosmetic products respond to consumers' desires for a more natural and healthy lifestyle," Cloud 9's managing director Dr Francis Scanlan said in a statement.

"Innocan has a proven high-level expertise and shared vision making them an ideal partner for us to develop these new markets."

Also in Thursday's statement, Innocan said it has engaged AGORACOM for a 12-month online marketing campaign to broaden its pool of potential investors. In consideration, Innocan will pay \$75,000 worth of shares payable in five equal installments during the period from August 2020 to July 2021.

Contact Angela at angela@proactiveinvestors.com

Follow her on Twitter @AHarmantas

Price: 0.27

Market Cap: \$47.34 m

1 Year Share Price Graph



Share Information

Code: INNO

Listing: CSE

52 week	High	Low
	0.35	0.05

Sector: Cannabis

Website: innocanpharma.com

Company Synopsis:

Innocan Pharma™ combines pharmaceutical experience with technological innovation to deliver the new generation of CBD integrated pharma and cosmetics products.

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of InnoCan Pharma named herein, including the promotion by the Company of InnoCan Pharma in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).